Cargando…

EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience

BACKGROUND: Antibiotic resistance is being a crucial issue in hospitals, and its control, passes through an appropriate use of antibiotics. To evaluate the prescriptive appropriateness, we introduced a new indicator which takes into account the rate of infections together with antimicrobial consumpt...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Avino, A, Grande, D, Schiattarella, A, Dionisi, P, Dolce, M, Miraglia, B A, Brandimarte, G, Carnali, M, Nasi, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596112/
http://dx.doi.org/10.1093/eurpub/ckad160.1034
_version_ 1785125027104948224
author D'Avino, A
Grande, D
Schiattarella, A
Dionisi, P
Dolce, M
Miraglia, B A
Brandimarte, G
Carnali, M
Nasi, G
author_facet D'Avino, A
Grande, D
Schiattarella, A
Dionisi, P
Dolce, M
Miraglia, B A
Brandimarte, G
Carnali, M
Nasi, G
author_sort D'Avino, A
collection PubMed
description BACKGROUND: Antibiotic resistance is being a crucial issue in hospitals, and its control, passes through an appropriate use of antibiotics. To evaluate the prescriptive appropriateness, we introduced a new indicator which takes into account the rate of infections together with antimicrobial consumption and the median time of treatment of each event. METHODS: The “Estimated Prescriptive Appropriateness Rate” (EPA-SCORE) “has been calculated for each group of bacteria, as the rate between the observed consumption of an antibiotic (DDD/1000days of hospitalization) and the expected one as if the same antibiotic had been used for 10 days exclusively for the observed infections for which it was indicated, according to the following formula: EPASCORE = (DDD observed/expected)*1/(N.of infections). Data from January 2020 and June 2022 were collected while restrictive and persuasive strategies of Antimicrobial Stewardship were implemented. Changes in EPA-SCORE were evaluated through the years. RESULTS: In our hospital, in the first semester of 2022 prevalence of ESBL+ Gram negative-infections was 0.90 cases/1000 doh/year. The observed consumption of drugs indicated for those infections was 86.9 DDD/1000 dof, whilst the expected one for the registered number of infections was 9.01 DDD/1000doh, with an EPASCORE of 10.37%. Regarding multi-drug-resistant gram negative-infections, prevalence was 1.48/1000doh/year; observed antibiotic consumption for them (whose prescription was restricted to ID specialists) was 43DDD/1000doh, whilts the expected DDD was 29.6 DDD/1000doh (EPASCORE 67.7%). Comparing data between 2022 and the same period of 2020, a significant increase in EPASCORE was detected (+4.2% and +7.1% for ESBL+ and MDR Gram- infections in 2022 respectively) CONCLUSIONS: Our date demonstrate that the EPASCORE represents a feasible indicator of appropriateness of antimicrobial prescription, and restrictive strategies of antimicrobial stewardship can help to improve its outcome. KEY MESSAGES: • Antimicrobial Stewardship has a leading role to face antimicrobial resistance. • EPA-SCORE is a feasible indicator to measure appropriateness of antimicrobial prescription.
format Online
Article
Text
id pubmed-10596112
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105961122023-10-25 EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience D'Avino, A Grande, D Schiattarella, A Dionisi, P Dolce, M Miraglia, B A Brandimarte, G Carnali, M Nasi, G Eur J Public Health Poster Displays BACKGROUND: Antibiotic resistance is being a crucial issue in hospitals, and its control, passes through an appropriate use of antibiotics. To evaluate the prescriptive appropriateness, we introduced a new indicator which takes into account the rate of infections together with antimicrobial consumption and the median time of treatment of each event. METHODS: The “Estimated Prescriptive Appropriateness Rate” (EPA-SCORE) “has been calculated for each group of bacteria, as the rate between the observed consumption of an antibiotic (DDD/1000days of hospitalization) and the expected one as if the same antibiotic had been used for 10 days exclusively for the observed infections for which it was indicated, according to the following formula: EPASCORE = (DDD observed/expected)*1/(N.of infections). Data from January 2020 and June 2022 were collected while restrictive and persuasive strategies of Antimicrobial Stewardship were implemented. Changes in EPA-SCORE were evaluated through the years. RESULTS: In our hospital, in the first semester of 2022 prevalence of ESBL+ Gram negative-infections was 0.90 cases/1000 doh/year. The observed consumption of drugs indicated for those infections was 86.9 DDD/1000 dof, whilst the expected one for the registered number of infections was 9.01 DDD/1000doh, with an EPASCORE of 10.37%. Regarding multi-drug-resistant gram negative-infections, prevalence was 1.48/1000doh/year; observed antibiotic consumption for them (whose prescription was restricted to ID specialists) was 43DDD/1000doh, whilts the expected DDD was 29.6 DDD/1000doh (EPASCORE 67.7%). Comparing data between 2022 and the same period of 2020, a significant increase in EPASCORE was detected (+4.2% and +7.1% for ESBL+ and MDR Gram- infections in 2022 respectively) CONCLUSIONS: Our date demonstrate that the EPASCORE represents a feasible indicator of appropriateness of antimicrobial prescription, and restrictive strategies of antimicrobial stewardship can help to improve its outcome. KEY MESSAGES: • Antimicrobial Stewardship has a leading role to face antimicrobial resistance. • EPA-SCORE is a feasible indicator to measure appropriateness of antimicrobial prescription. Oxford University Press 2023-10-24 /pmc/articles/PMC10596112/ http://dx.doi.org/10.1093/eurpub/ckad160.1034 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Displays
D'Avino, A
Grande, D
Schiattarella, A
Dionisi, P
Dolce, M
Miraglia, B A
Brandimarte, G
Carnali, M
Nasi, G
EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience
title EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience
title_full EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience
title_fullStr EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience
title_full_unstemmed EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience
title_short EPASCORE: A new indicator for prescriptive appropriateness of antimicrobials: our experience
title_sort epascore: a new indicator for prescriptive appropriateness of antimicrobials: our experience
topic Poster Displays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596112/
http://dx.doi.org/10.1093/eurpub/ckad160.1034
work_keys_str_mv AT davinoa epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT granded epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT schiattarellaa epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT dionisip epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT dolcem epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT miragliaba epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT brandimarteg epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT carnalim epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience
AT nasig epascoreanewindicatorforprescriptiveappropriatenessofantimicrobialsourexperience